• 教授ご挨拶
  • 診療案内
  • メンバー
  • 研究内容
  • 研究実績
  • ニュース
  • 募集情報
  • アクセス

研究実績

HOME > 研究実績

論文

2018年

  1. Hiramatsu K, Serada S, Enomoto T, Takahashi Y, Nakagawa S, Nojima S, Morimoto A, Matsuzaki S, Yokoyama T, Takahashi T, Fujimoto M, Takemori H, Ueda Y, Yoshino K, Morii E, Kimura T, Naka T.
    LSR antibody therapy inhibits ovarian epithelial tumor growth by inhibiting lipid uptake.
    Cancer Res. 2018 Jan 15;78(2):516-527.[PubMed]
  2. Matsuzaki S, Serada S, Hiramatsu K, Nojima S, Matsuzaki S, Ueda Y, Ohkawara T, Mabuchi S, Fujimoto M, Morii E, Yoshino K, Kimura T, Naka T.
    Anti-glypican-1 antibody-drug conjugate exhibits potent preclinical antitumor activity against glypican-1 positive uterine cervical cancer.
    Int J Cancer. 2018 Mar 1;142(5):1056-1066.[PubMed]
  3. Lee H, Fujimoto M, Ohkawara T, Honda H, Serada S, Terada Y, Naka T.
    Leucine rich α-2 glycoprotein is a potential urinary biomarker for renal tubular injury.
    Biochem Biophys Res Commun 2018 Apr 15;498(4):1045-1051.[PubMed]
  4. Sugase T, Takahashi T, Serada S, Fujimoto M, Ohkawara T, Hiramatsu K, Nishida T, Hirota S, Saito Y, Tanaka K, Miyazaki Y, Makino T, Kurokawa Y, Yamasaki M, Nakajima K, Hanasaki K, Kishimoto T, Mori M, Doki Y, Naka T.
    SOCS1 gene therapy has antitumor effects in imatinib-resistant gastrointestinal stromal tumor cells through FAK/PI3 K signaling.
    Gastric Cancer 2018 Apr 5.[PubMed]

2017年

  1. Shinzaki S, Matsuoka K, Iijima H, Mizuno S, Serada S, Fujimoto M, Arai N, Koyama N, Morii E, Watanabe M, Hibi T, Kanai T, Takehara T, Naka T.
    Leucine-rich Alpha-2 Glycoprotein is a Serum Biomarker of Mucosal Healing in Ulcerative Colitis.
    J Crohns Colitis. 2017 Jan;11(1):84-91. [PubMed]
  2. Hosono Y, Nakashima R, Serada S, Murakami K, Imura Y, Yoshifuji H, Ohmura K, Naka T, Mimori T.
    Splicing factor proline/glutamine-rich is a novel autoantigen of dermatomyositis and associated with anti-melanoma differentiation-associated gene 5 antibody.
    J Autoimmun. 2017 Feb;77:116-122. [PubMed]
  3. Harada E, Serada S, Fujimoto M, Takahashi Y, Takahashi T, Hara H, Nakatsuka R, Sugase T, Nishigaki T, Saito Y, Hiramatsu K, Nojima S, Mitsuo R, Ohkawara T, Morii E, Mori M, Doki Y, Kaneda Y, Naka T.
    Glypican-1 targeted antibody-based therapy induces preclinical antitumor activity against esophageal squamous cell carcinoma.
    Oncotarget. 2017 Apr 11;8(15):24741-24752. [PubMed]
  4. Takahashi T, Elzawahry A, Mimaki S, Furukawa E, Nakatsuka R, Nakamura H, Nishigaki T, Serada S, Naka T, Hirota S, Shibata T, Tsuchihara K, Nishida T, Kato M.
    Genomic and transcriptomic analysis of imatinib resistance in gastrointestinal stromal tumors.
    Genes Chromosomes Cancer. 2017 Apr;56(4):303-313. [PubMed]
  5. Shinzaki S, Iijima H, Fujii H, Kamada Y, Naka T, Takehara T, Miyoshi E.
    A novel pathogenesis of inflammatory bowel disease from the perspective of glyco-immunology.
    J Biochem. 2017 May 1;161(5):409-415. [PubMed]
  6. Nakajima H, Serada S, Fujimoto M, Naka T, Sano S.
    Leucine-rich α-2 glycoprotein is an innovative biomarker for psoriasis.
    J Dermatol Sci. 2017 May;86(2):170-174. [PubMed]
  7. Sugase T, Takahashi T, Serada S, Nakatsuka R, Fujimoto M, Ohkawara T, Hara H, Nishigaki T, Tanaka K, Miyazaki Y, Makino T, Kurokawa Y, Yamasaki M, Nakajima K, Takiguchi S, Kishimoto T, Mori M, Doki Y, Naka T.
    Suppressor of cytokine signaling-1 gene therapy induces potent antitumor effect in patient-derived esophageal squamous cell carcinoma xenograft mice.
    Int J Cancer. 2017 Jun 1;140(11):2608-2621. [PubMed]
  8. Urushima H, Fujimoto M, Mishima T, Ohkawara T, Honda H, Lee H, Kawahata H, Serada S, Naka T.
    Leucine-rich alpha 2 glycoprotein promotes Th17 differentiation and collagen-induced arthritis in mice through enhancement of TGF-β-Smad2 signaling in naïve helper T cells.
    Arthritis Res Ther. 2017 Jun 14;19(1):137. [PubMed]
  9. Yamamoto M, Takahashi T, Serada S, Sugase T, Tanaka K, Miyazaki Y, Makino T, Kurokawa Y, Yamasaki M, Nakajima K, Takiguchi S, Naka T, Mori M, Doki Y.
    Overexpression of leucine-rich α2-glycoprotein-1 is a prognostic marker and enhances tumor migration in gastric cancer.
    Cancer Sci. 2017 Oct;108(10):2052-2060. [PubMed]
  10. Sugase T, Takahashi T, Serada S, Fujimoto M, Hiramatsu K, Ohkawara T, Tanaka K, Miyazaki Y, Makino T, Kurokawa Y, Yamasaki M, Nakajima K, Kishimoto T, Mori M, Doki Y, Naka T.
    SOCS1 gene therapy improves radiosensitivity and enhances irradiation-induced DNA damage in esophageal squamous cell carcinoma.
    Cancer Res. 2017 Dec 15;77(24):6975-6986.[PubMed]
  11. Honda H, Fujimoto M, Serada S, Urushima H, Mishima T, Lee H, Ohkawara T, Kohno N, Hattori N, Yokoyama A, Naka T.
    Leucine-rich α-2 glycoprotein promotes lung fibrosis by modulating TGF-β signaling in fibroblasts.
    Physiol Rep. 2017 Dec;5(24). pii: e13556.[PubMed]

2016年

  1. Yang L, Murota H, Shindo S, Yang F, Serada S, Fujimoto M, Naka T, Katayama I.
    Increased serum CXCR2 ligand levels in livedo vasculopathy with winter ulcerations: Possible contribution of neutrophil recruitment to lesional skin.
    J Dermatol Sci. 82(1):57-9. 2016. [PubMed]
  2. Mahmoud NF, Kawabata A, Tang H, Wakata A, Wang B, Serada S, Naka T, Mori Y.
    Human herpesvirus 6 U11 protein is critical for virus infection.
    Virology. 2016 Feb;489:151-7. [PubMed]
  3. Kumagai S, Nakayama H, Fujimoto M, Honda H, Serada S, Ishibashi-Ueda H, Kasai A, Obana M, Sakata Y, Sawa Y, Fujio Y, Naka T.
    Myeloid cell-derived LRG attenuates adverse cardiac remodelling after myocardial infarction.
    Cardiovasc Res. 2016 Feb 1;109(2):272-82. [PubMed]
  4. Yamada K, Miyamoto Y, Tsujii A, Moriyama T, Ikuno Y, Shiromizu T, Serada S, Fujimoto M, Tomonaga T, Naka T, Yoneda Y, Oka M.
    Cell surface localization of importin α1/KPNA2 affects cancer cell proliferation by regulating FGF1 signalling.
    Sci Rep. 2016 Feb 18;6:21410. [PubMed]
  5. Hiramatsu K, Yoshino K, Serada S, Yoshihara K, Hori Y, Fujimoto M, Matsuzaki S, Egawa-Takata T, Kobayashi E, Ueda Y, Morii E, Enomoto T, Naka T, Kimura T.
    Similar protein expression profiles of ovarian and endometrial high-grade serous carcinomas.
    Br J Cancer. 2016 Mar 1;114(5):554-61. [PubMed]
  6. Yotsui I, Serada S, Naka T, Saruhashi M, Taji T, Hayashi T, Quatrano RS, Sakata Y.
    Large-scale proteome analysis of abscisic acid and ABSCISIC ACID INSENSITIVE3-dependent proteins related to desiccation tolerance in Physcomitrella patens.
    Biochem Biophys Res Commun. 2016 Mar 18;471(4):589-95. [PubMed]
  7. Han Y, Ripley B, Serada S, Naka T, Fujimoto M.
    Interleukin-6 Deficiency Does Not Affect Motor Neuron Disease Caused by Superoxide Dismutase 1 Mutation.
    PLoS One. 2016 Apr 12;11(4):e0153399. [PubMed]
  8. Hara H, Takahashi T, Serada S, Fujimoto M, Ohkawara T, Nakatsuka R, Harada E, Nishigaki T, Takahashi Y, Nojima S, Miyazaki Y, Makino T, Kurokawa Y, Yamasaki M, Miyata H, Nakajima K, Takiguchi S, Morii E, Mori M, Doki Y, Naka T.
    Overexpression of glypican-1 implicates poor prognosis and their chemoresistance in oesophageal squamous cell carcinoma.
    Br J Cancer. 2016 Jun 28;115(1):66-75. [PubMed]
  9. Wada N, Kurokawa Y, Takahashi T, Hamakawa T, Hirota S, Naka T, Miyazaki Y, Makino T, Yamasaki M, Nakajima K, Takiguchi S, Mori M, Doki Y.
    Detecting Secondary C-KIT Mutations in the Peripheral Blood of Patients with Imatinib-Resistant Gastrointestinal Stromal Tumor.
    Oncology. 2016;90(2):112-7. [PubMed]
  10. Honda H, Fujimoto M, Miyamoto S, Ishikawa N, Serada S, Hattori N, Nomura S, Kohno N, Yokoyama A, Naka T.
    Sputum Leucine-Rich Alpha-2 Glycoprotein as a Marker of Airway Inflammation in Asthma.
    PLoS One. 2016 Sep 9;11(9):e0162672. [PubMed]

2015年

  1. Furukawa K, Kawamoto K, Eguchi H, Tanemura M, Tanida T, Tomimaru Y, Akita H, Hama N, Wada H, Kobayashi S, Nonaka Y, Takamatsu S, Shinzaki S, Kumada T, Satomura S, Ito T, Serada S, Naka T, Mori M, Doki Y, Miyoshi E, Nagano H.
    Clinicopathological Significance of Leucine-Rich α2-Glycoprotein-1 in Sera of Patients With Pancreatic Cancer.
    Pancreas. 2015 Jan;44(1):93-8. [PubMed]
  2. Yang L, Fujimoto M, Murota H, Serada S, Fujimoto M, Honda H, Yamada K, Suzuki K, Nishikawa A, Hosono Y, Yoneda Y, Takehara K, Imura Y, Mimori T, Takeuchi T, Katayama I, Naka T.
    Proteomic identification of heterogeneous nuclear ribonucleoprotein K as a novel cold-associated autoantigen in patients with secondary Raynaud's phenomenon.
    Rheumatology (Oxford). 2015 Feb;54(2):349-58. [PubMed]
  3. Takemoto N, Serada S, Fujimoto M, Honda H, Ohkawara T, Takahashi T, Nomura S, Inohara H, Naka T.
    Leucine-rich α-2-glycoprotein promotes TGFβ1-mediated growth suppression in the Lewis lung carcinoma cell lines.
    Oncotarget. 2015 May 10;6(13):11009-22. [PubMed]
  4. Sanosaka M, Fujimoto M, Ohkawara T, Nagatake T, Itoh Y, Kagawa M, Kumagai A, Fuchino H, Kunisawa J, Naka T, Takemori H.
    Salt-inducible kinase 3 deficiency exacerbates lipopolysaccharide-induced endotoxin shock accompanied by increased levels of pro-inflammatory molecules in mice.
    Immunology. 2015 Jun;145(2):268-78. [PubMed]
  5. Fujimoto M, Serada S, Suzuki K, Nishikawa A, Ogata A, Nanki T, Hattori K, Kohsaka H, Miyasaka N, Takeuchi T, Naka T.
    Leucine-rich α2 -glycoprotein as a potential biomarker for joint inflammation during anti-interleukin-6 biologic therapy in rheumatoid arthritis.
    Arthritis Rheumatol. 2015 May;67(8):2056-60. [PubMed]
  6. Natatsuka R, Takahashi T, Serada S, Fujimoto M, Ookawara T, Nishida T, Hara H, Nishigaki T, Harada E, Murakami T, Miyazaki Y, Makino T, Kurokawa Y, Yamasaki M, Miyata H, Nakajima K, Takiguchi S, Kishimoto T, Mori M, Doki Y, Naka T.
    Gene therapy with SOCS1 for gastric cancer induces G2/M arrest and has an antitumour effect on peritoneal carcinomatosis.
    Br J Cancer. 2015 Jul 28;113(3):433-42. [PubMed]
  7. Tagami-Nagata N, Serada S, Fujimoto M, Tanemura A, Nakatsuka R, Ohkawara T, Murota H, Kishimoto T, Katayama I, Naka T.
    Suppressor of cytokine signalling-1 induces significant preclinical antitumor effect in malignant melanoma cells.
    Exp Dermatol. 2015 Nov;24(11):864-71. [PubMed]
  8. Iwahashi C, Fujimoto M, Nomura S, Serada S, Nakai K, Ohguro N, Nishida K, Naka T.
    CTLA4-Ig suppresses development of experimental autoimmune uveitis in the induction and effector phases: Comparison with blockade of interleukin-6.
    Exp Eye Res. 2015 Nov;140:53-64. [PubMed]
  9. Hiramatsu K, Serada S, Kobiyama K, Nakagawa S, Morimoto A, Matsuzaki S, Ueda Y, Fujimoto M, Yoshino K, Ishii KJ, Enomoto T, Kimura T, Naka T.
    CpG oligodeoxynucleotides potentiate the antitumor activity of anti-BST2 antibody.
    Cancer Sci. 2015 Oct;106(10):1474-8. [PubMed]

2014年

  1. Sadaoka T, Serada S, Kato J, Hayashi M, Gomi Y, Naka T, Yamanishi K, Mori Y.
    Varicella-zoster virus ORF49 functions in the efficient production of progeny virus through its interaction with essential tegument protein ORF44.
    J Virol. 2014 Jan;88(1):188-201. [PubMed]
  2. Ota M, Serada S, Naka T, Mori Y.
    MHC class I molecules are incorporated into human herpesvirus-6 viral particles and released into the extracellular environment.
    Microbiol Immunol. 2014 Feb;58(2):119-25. [PubMed]
  3. Matsuzaki S, Enomoto T, Serada S, Yoshino K, Nagamori S, Morimoto A, Yokoyama T, Kim A, Kimura T, Ueda Y, Fujita M, Fujimoto M, Kanai Y, Kimura T, Naka T.
    Annexin A4-conferred platinum resistance is mediated by the copper transporter ATP7A.
    Int J Cancer. 2014 Apr 15;134(8):1796-809. [PubMed]
  4. Oji Y, Tatsumi N, Fukuda M, Nakatsuka S, Aoyagi S, Hirata E, Nanchi I, Fujiki F, Nakajima H, Yamamoto Y, Shibata S, Nakamura M, Hasegawa K, Takagi S, Fukuda I, Hoshikawa T, Murakami Y, Mori M, Inoue M, Naka T, Tomonaga T, Shimizu Y, Nakagawa M, Hasegawa J, Nezu R, Inohara H, Izumoto S, Nonomura N, Yoshimine T, Okumura M, Morii E, Maeda H, Nishida S, Hosen N, Tsuboi A, Oka Y, Sugiyama H.
    The translation elongation factor eEF2 is a novel tumor‑associated antigen overexpressed in various types of cancers.
    Int J Oncol. 2014 May;44(5):1461-9. [PubMed]
  5. Kotobuki Y, Yang L, Serada S, Tanemura A, Yang F, Nomura S, Kudo A, Izuhara K, Murota H, Fujimoto M, Katayama I, Naka T.
    Periostin accelerates human malignant melanoma progression by modifying the melanoma microenvironment.
    Pigment Cell Melanoma Res. 2014 Jul;27(4):630-9. [PubMed]
  6. Yang L, Murota H, Serada S, Fujimoto M, Kudo A, Naka T, Katayama I.
    Histamine contributes to tissue remodeling via periostin expression.
    J Invest Dermatol. 2014 Aug;134(8):2105-2113. [PubMed]
  7. Morimoto A, Serada S, Enomoto T, Kim A, Matsuzaki S, Takahashi T, Ueda Y, Yoshino K, Fujita M, Fujimoto M, Kimura T, Naka T.
    Annexin A4 induces platinum resistance in a chloride-and calcium-dependent manner.
    Oncotarget. 2014 Sep 15;5(17):7776-87. [PubMed]

2013年

  1. Iwahori K, Serada S, Fujimoto M, Ripley B, Nomura S, Mizuguchi H, Shimada K, Takahashi T, Kawase I, Kishimoto T, Naka T.
    SOCS-1 gene delivery cooperates with cisplatin plus pemetrexed to exhibit preclinical antitumor activity against malignant pleural mesothelioma.
    Int J Cancer. 2013 Jan 15;132(2):459-71. [PubMed]
  2. Yokoyama T, Enomoto T, Serada S, Morimoto A, Matsuzaki S, Ueda Y, Yoshino K, Fujita M, Kyo S, Iwahori K, Fujimoto M, Kimura T, Naka T.
    Plasma membrane proteomics identifies BST2 as a potential therapeutic target in endometrial carcinoma.
    Int J Cancer. 2013 Jan 15;132(2):472-84. [PubMed]
  3. Shinzaki S, Kuroki E, Iijima H, Tatsunaka N, Ishii M, Fujii H, Kamada Y, Kobayashi T, Shibukawa N, Inoue T, Tsujii M, Takeishi S, Mizushima T, Ogata A, Naka T, Plevy SE, Takehara T, Miyoshi E.
    Lectin-based immunoassay for aberrant IgG glycosylation as the biomarker for Crohn's disease.
    Inflamm Bowel Dis. 2013 Feb;19(2):321-31. [PubMed]
  4. Nishioka C, Ikezoe T, Furihata M, Yang J, Serada S, Naka T, Nobumoto A, Kataoka S, Tsuda M, Udaka K, Yokoyama A.
    CD34⁺/CD38⁻ acute myelogenous leukemia cells aberrantly express CD82 which regulates adhesion and survival of leukemia stem cells.
    Int J Cancer. 2013 May 1;132(9):2006-19. [PubMed]
  5. He P, Kuhara H, Tachibana I, Jin Y, Takeda Y, Tetsumoto S, Minami T, Kohmo S, Hirata H, Takahashi R, Inoue K, Nagatomo I, Kida H, Kijima T, Naka T, Morii E, Kawase I, Kumanogoh A.
    Calretinin mediates apoptosis in small cell lung cancer cells expressing tetraspanin CD9.
    FEBS Open Bio. 2013 May 10;3:225-30. [PubMed]
  6. Tang H, Serada S, Kawabata A, Ota M, Hayashi E, Naka T, Yamanishi K, Mori Y.
    CD134 is a cellular receptor specific for human herpesvirus-6B entry.
    Proc Natl Acad Sci U S A. 2013 May 28;110(22):9096-9. [PubMed]
  7. Yamada M, Mugnai G, Serada S, Yagi Y, Naka T, Sekiguchi K.
    Substrate-attached materials are enriched with tetraspanins and are analogous to the structures associated with rear-end retraction in migrating cells.
    Cell Adhesion & Migration. Cell Adh Migr. 2013 May-Jun;7(3):304-14. [PubMed]
  8. Ishii H, Tanabe S, Ueno M, Kubo T, Kayama H, Serada S, Fujimoto M, Takeda K, Naka T, Yamashita T.
    ifn-γ-dependent secretion of IL-10 from Th1 cells and microglia/macrophages contributes to functional recovery after spinal cord injury.
    Cell Death Dis. 2013 Jul 4;4:e710. [PubMed]
  9. Umegaki-Arao N, Tamai K, Nimura K, Serada S, Naka T, Nakano H, Katayama I.
    Karyopherin alpha2 is essential for rRNA transcription and protein synthesis in proliferative keratinocytes.
    PLoS One. 2013 Oct 3;8(10):e76416. [PubMed]
  10. Shimada K, Serada S, Fujimoto M, Nomura S, Nakatsuka R, Harada E, Iwahori K, Tachibana I, Takahashi T, Kumanogoh A, Kishimoto T, Naka T.
    Molecular mechanism underlying the antiproliferative effect of suppressor of cytokine signaling-1 in non-small-cell lung cancer cells.
    Cancer Sci. 2013 Nov;104(11):1483-91. [PubMed]
  11. Takahashi T, Serada S, Ako M, Fujimoto M, Miyazaki Y, Nakatsuka R, Ikezoe T, Yokoyama A, Taguchi T, Shimada K, Kurokawa Y, Yamasaki M, Miyata H, Nakajima K, Takiguchi S, Mori M, Doki Y, Naka T, Nishida T.
    New findings of kinase switching in gastrointestinal stromal tumor under imatinib using phosphoproteomic analysis.
    Int J Cancer. 2013 Dec 1;133(11):2737-43. [PubMed]

2012年

  1. Kitaba S, Murota H, Terao M, Azukizawa H, Terabe F, Shima Y, Fujimoto M, Tanaka T, Naka T, Kishimoto T, Katayama I.
    Blockade of interleukin-6 receptor alleviates disease in mouse model of scleroderma.
    Am J Pathol. 2012 Jan;180(1):165-76. [PubMed]
  2. Souma Y, Nishida T, Serada S, Iwahori K, Takahashi T, Fujimoto M, Ripley B, Nakajima K, Miyazaki Y, Mori M, Doki Y, Sawa Y, Naka T.
    Antiproliferative effect of SOCS-1 through the suppression of STAT3 and p38 MAPK activation in gastric cancer cells.
    Int J Cancer. 2012 Sep 15;131(6):1287-96. [PubMed]
  3. Kotobuki Y, Tanemura A, Yang L, Itoi S, Wataya-Kaneda M, Murota H, Fujimoto M, Serada S, Naka T, Katayama I.
    Dysregulation of melanocyte function by Th17-related cytokines: significance of Th17 cell infiltration in autoimmune vitiligo vulgaris.
    Pigment Cell Melanoma Res. 2012 Mar;25(2):219-30. [PubMed]
  4. Serada S, Fujimoto M, Terabe F, Iijima H, Shinzaki S, Matsuzaki S, Ohkawara T, Nezu R, Nakajima S, Kobayashi T, Plevy SE, Takehara T, Naka T.
    Serum leucine-rich alpha-2 glycoprotein is a disease activity biomarker in ulcerative colitis.
    Inflamm Bowel Dis. 2012 Nov;18(11):2169-79. [PubMed]
  5. Ontsuka K, Kotobuki Y, Shiraishi H, Serada S, Ohta S, Tanemura A, Yang L, Fujimoto M, Arima K, Suzuki S, Murota H, Toda S, Kudo A, Conway SJ, Narisawa Y, Katayama I, Izuhara K, Naka T.
    Periostin, a matricellular protein, accelerates cutaneous wound repair by activating dermal fibroblasts.
    Exp Dermatol. 2012 May;21(5):331-6. [PubMed]
  6. Iwahori K, Suzuki H, Kishi Y, Fujii Y, Uehara R, Okamoto N, Kobayashi M, Hirashima T, Kawase I, Naka T.
    Serum HE4 as a diagnostic and prognostic marker for lung cancer.
    Tumour Biol. 2012 Aug;33(4):1141-9. [PubMed]
  7. Uebi T, Itoh Y, Hatano O, Kumagai A, Sanosaka M, Sasaki T, Sasagawa S, Doi J, Tatsumi K, Mitamura K, Morii E, Aozasa K, Kawamura T, Okumura M, Nakae J, Takikawa H, Fukusato T, Koura M, Nish M, Hamsten A, Silveira A, Bertorello AM, Kitagawa K, Nagaoka Y, Kawahara H, Tomonaga T, Naka T, Ikegawa S, Tsumaki N, Matsuda J, Takemori H.
    Involvement of SIK3 in glucose and lipid homeostasis in mice.
    PLoS One. 2012;7(5):e37803. [PubMed]
  8. Tajiri K, Imanaka-Yoshida K, Matsubara A, Tsujimura Y, Hiroe M, Naka T, Shimojo N, Sakai S, Aonuma K, Yasutomi Y.
    Suppressor of cytokine signaling 1 DNA administration inhibits inflammatory and pathogenic responses in autoimmune myocarditis.
    J Immunol. 2012 Aug 15;189(4):2043-53. [PubMed]
  9. Yang L, Serada S, Fujimoto M, Terao M, Kotobuki Y, Kitaba S, Matsui S, Kudo A, Naka T, Murota H, Katayama I.
    Periostin facilitates skin sclerosis via PI3K/Akt dependent mechanism in a mouse model of scleroderma.
    PLoS One. 2012;7(7):e41994. [PubMed]
  10. Ishii H, Jin X, Ueno M, Tanabe S, Kubo T, Serada S, Naka T, Yamashita T.
    Adoptive transfer of Th1-conditioned lymphocytes promotes axonal remodeling and functional recovery after spinal cord injury.
    Cell Death Dis. 2012 Aug 9;3:e363. [PubMed]

2011年

  1. Terabe F, Fujimoto M, Serada S, Shinzaki S, Iijima H, Tsujii M, Hayashi N, Nomura S, Kawahata H, Jang MH, Miyasaka M, Mihara M, Ohsugi Y, Kishimoto T, Naka T.
    Comparative analysis of the effects of anti-IL-6 receptor mAb and anti-TNF mAb treatment on CD4+ T-cell responses in murine colitis.
    Inflamm Bowel Dis. 2011 Feb;17(2):491-502. [PubMed]
  2. Iwahori K, Serada S, Fujimoto M, Nomura S, Osaki T, Lee CM, Mizuguchi H, Takahashi T, Ripley B, Okumura M, Kawase I, Kishimoto T, Naka T.
    Overexpression of SOCS3 exhibits preclinical antitumor activity against malignant pleural mesothelioma.
    Int J Cancer. 2011 Aug 15;129(4):1005-17. [PubMed]
  3. Fujimoto M, Nakano M, Terabe F, Kawahata H, Ohkawara T, Han Y, Ripley B, Serada S, Nishikawa T, Kimura A, Nomura S, Kishimoto T, Naka T.
    The influence of excessive IL-6 production in vivo on the development and function of Foxp3+ regulatory T cells.
    J Immunol. 2011 Jan 1;186(1):32-40. [PubMed]
  4. Haruta H, Ohguro N, Fujimoto M, Hohki S, Terabe F, Serada S, Nomura S, Nishida K, Kishimoto T, Naka T.
    Blockade of interleukin-6 signaling suppresses not only th17 but also interphotoreceptor retinoid binding protein-specific Th1 by promoting regulatory T cells in experimental autoimmune uveoretinitis.
    Invest Ophthalmol Vis Sci. 2011 May 17;52(6):3264-71. [PubMed]
  5. Yamashita T, Iwakura T, Matsui K, Kawaguchi H, Obana M, Hayama A, Maeda M, Izumi Y, Komuro I, Ohsugi Y, Fujimoto M, Naka T, Kishimoto T, Nakayama H, Fujio Y.
    IL-6-mediated Th17 differentiation through RORγt is essential for the initiation of experimental autoimmune myocarditis.
    Cardiovascular Research. Cardiovasc Res. 2011 Sep 1;91(4):640-8. [PubMed]

2010年

  1. Serada S, Fujimoto M, Ogata A, Terabe F, Hirano T, Iijima H, Shinzaki S, Nishikawa T, Ohkawara T, Iwahori K, Ohguro N, Kishimoto T, Naka T.
    iTRAQ-based proteomic identification of leucine-rich alpha-2 glycoprotein as a novel inflammatory biomarker in autoimmune diseases.
    Ann Rheum Dis. 2010 Apr;69(4):770-4. [PubMed]
  2. Nomura T, Abe Y, Kamada H, Shibata H, Kayamuro H, Inoue M, Kawara T, Arita S, Furuya T, Yamashita T, Nagano K, Yoshikawa T, Yoshioka Y, Mukai Y, Nakagawa S, Taniai M, Ohta T, Serada S, Naka T, Tsunoda S, Tsutsumi Y.
    Therapeutic effect of PEGylated TNFR1-selective antagonistic mutant TNF in experimental autoimmune encephalomyelitis mice.
    J Control Release. 2011 Jan 5;149(1):8-14. [PubMed]
  3. Akita H, Kogure K, Moriguchi R, Nakamura Y, Higashi T, Nakamura T, Serada S, Fujimoto M, Naka T, Futaki S, Harashima H.
    Nanoparticles for ex vivo siRNA delivery to dendritic cells for cancer vaccines: programmed endosomal escape and dissociation.
    J Control Release. 2010 May 10;143(3):311-7. [PubMed]
  4. Ripley BJ, Fujimoto M, Serada S, Ohkawara T, Nishikawa T, Terabe F, Matsukawa Y, Stephanou A, Knight RA, Isenberg DA, Latchman DS, Kishimoto T, Naka T.
    Green tea polyphenol epigallocatechin gallate inhibits cell signaling by inducing SOCS1 gene expression.
    Int Immunol. 2010 May;22(5):359-66. [PubMed]
  5. Hohki S, Ohguro N, Haruta H, Nakai K, Terabe F, Serada S, Fujimoto M, Nomura S, Kawahata H, Kishimoto T, Naka T.
    Blockade of interleukin-6 signaling suppresses experimental autoimmune uveoretinitis by the inhibition of inflammatory Th17 responses.
    Exp Eye Res. 2010 Aug;91(2):162-70. [PubMed]

2009年

  1. Kim A, Enomoto T, Serada S, Ueda Y, Takahashi T, Ripley B, Miyatake T, Fujita M, Lee CM, Morimoto K, Fujimoto M, Kimura T, Naka T.
    Enhanced expression of Annexin A4 in clear cell carcinoma of the ovary and its association with chemoresistance to carboplatin.
    Int J Cancer. 2009 Nov 15;125(10):2316-22. [PubMed]
  2. Kimura A, Naka T, Nakahama T, Chinen I, Masuda K, Nohara K, Fujii-Kuriyama Y, Kishimoto T.
    Aryl hydrocarbon receptor in combination with Stat1 regulates LPS-induced inflammatory responses.
    J Exp Med. 2009 Aug 31;206(9):2027-35. [PubMed]
  3. Tanaka S, Yoshimoto T, Naka T, Nakae S, Iwakura Y, Cua D, Kubo M.
    Natural occurring IL-17 producing T cells regulate the initial phase of neutrophil mediated airway responses.
    J Immunol. 2009 Dec 1;183(11):7523-30. [PubMed]

2008年

  1. Takahashi T, Naka T, Fujimoto M, Serada S, Horino J, Terabe F, Hirota S, Miyoshi E, Hirai T, Nakajima K, Nishitani A, Souma Y, Sawa Y, Nishida T.
    Aberrant expression of glycosylation in juvenile gastrointestinal stromal tumors.
    Proteomics Clin Appl. 2008 Sep;2(9):1246-54. [PubMed]
  2. Nakashima T, Yokoyama A, Onari Y, Shoda H, Haruta Y, Hattori N, Naka T, Kohno N.
    Suppressor of cytokine signaling 1 inhibits pulmonary inflammation and fibrosis.
    J Allergy Clin Immunol. 2008 May;121(5):1269-76. [PubMed]
  3. Seki E, Kondo Y, Iimuro Y, Naka T, Son G, Kishimoto T, Fujimoto J, Tsutsui H, Nakanishi K.
    Demonstration of cooperative contribution of MET- and EGFR-mediated STAT3 phosphorylation to liver regeneration by exogenous suppressor of cytokine signalings.
    J Hepatol. 2008 Feb;48(2):237-45. [PubMed]
  4. Nishikawa T, Hagihara K, Serada S, Isobe T, Matsumura A, Song J, Tanaka T, Kawase I, Naka T, Yoshizaki K.
    Transcriptional complex formation of c-Fos, STAT3, and hepatocyte NF-1 alpha is essential for cytokine-driven C-reactive protein gene expression.
    J Immunol. 2008 Mar 1;180(5):3492-501. [PubMed]
  5. Yamaguchi H, Takagi J, Miyamae T, Yokota S, Fujimoto T, Nakamura S, Ohshima S, Naka T, Nagata S.
    Milk fat globule EGF factor 8 in the serum of human patients of systemic lupus erythematosus.
    J Leukoc Biol. 2008 May;83(5):1300-7. [PubMed]
  6. Serada S, Fujimoto M, Mihara M, Koike N, Ohsugi Y, Nomura S, Yoshida H, Nishikawa T, Terabe F, Ohkawara T, Takahashi T, Ripley B, Kimura A, Kishimoto T, Naka T.
    IL-6 blockade inhibits the induction of myelin antigen-specific Th17 cells and Th1 cells in experimental autoimmune encephalomyelitis.
    Proc Natl Acad Sci U S A. 2008 Jul 1;105(26):9041-6. [PubMed]
  7. Horino J, Fujimoto M, Terabe F, Serada S, Takahashi T, Soma Y, Tanaka K, Chinen T, Yoshimura A, Nomura S, Kawase I, Hayashi N, Kishimoto T, Naka T.
    Suppressor of cytokine signaling-1 ameliorates dextran sulfate sodium-induced colitis in mice.
    Int Immunol. 2008 Jun;20(6):753-62. [PubMed]
  8. Yu CR, Mahdi RM, Liu X, Zhang A, Naka T, Kishimoto T, Egwuagu CE.
    SOCS1 regulates CCR7 expression and migration of CD4+ T cells into peripheral tissues.
    J Immunol. 2008 Jul 15;181(2):1190-8. [PubMed]
  9. Kimura A, Naka T, Nohara K, Fujii-Kuriyama Y, Kishimoto T.
    Aryl hydrocarbon receptor regulates Stat1 activation and participates in the development of Th17 cells.
    Proc Natl Acad Sci U S A. 2008 Jul 15;105(28):9721-6. [PubMed]
  10. Iwahori K, Osaki T, Serada S, Fujimoto M, Suzuki H, Kishi Y, Yokoyama A, Hamada H, Fujii Y, Yamaguchi K, Hirashima T, Matsui K, Tachibana I, Nakamura Y, Kawase I, Naka T.
    Megakaryocyte potentiating factor as a tumor marker of malignant pleural mesothelioma: evaluation in comparison with mesothelin.
    Lung Cancer. 2008 Oct;62(1):45-54. [PubMed]
  11. Fujimoto M, Serada S, Mihara M, Uchiyama Y, Yoshida H, Koike N, Ohsugi Y, Nishikawa T, Ripley B, Kimura A, Kishimoto T, Naka T.
    Interleukin-6 blockade suppresses autoimmune arthritis in mice by the inhibition of inflammatory Th17 responses.
    Arthritis Rheum. 2008 Dec;58(12):3710-9. [PubMed]

2007年

  1. Shoda H, Yokoyama A, Nishino R, Nakashima T, Ishikawa N, Haruta Y, Hattori N, Naka T, Kohno N.
    Overproduction of collagen and diminished SOCS1 expression are causally linked in fibroblasts from idiopathic pulmonary fibrosis.
    Biochem Biophys Res Commun. 2007 Feb 23;353(4):1004-10. [PubMed]
  2. Kanatani Y, Usui I, Ishizuka K, Bukhari A, Fujisaka S, Urakaze M, Haruta T, Kishimoto T, Naka T, Kobayashi M.
    Effects of pioglitazone on suppressor of cytokine signaling 3 expression: potential mechanisms for its effects on insulin sensitivity and adiponectin expression.
    Diabetes. 2007 Mar;56(3):795-803. [PubMed]
  3. Ohshima M, Yokoyama A, Ohnishi H, Hamada H, Kohno N, Higaki J, Naka T.
    Overexpression of suppressor of cytokine signalling-5 augments eosinophilic airway inflammation in mice.
    Clin Exp Allergy. 2007 May;37(5):735-42. [PubMed]
  4. He P, Naka T, Serada S, Fujimoto M, Tanaka T, Hashimoto S, Shima Y, Yamadori T, Suzuki H, Hirashima T, Matsui K, Shiono H, Okumura M, Nishida T, Tachibana I, Norioka N, Norioka S, Kawase I.
    Proteomics-based identification of alpha-enolase as a tumor antigen in non-small lung cancer.
    Cancer Sci. 2007 Aug;98(8):1234-40. [PubMed]
  5. Kimura A, Naka T, Kishimoto T.
    IL-6-dependent and -independent pathways in the development of interleukin 17-producing T helper cells.
    Proc Natl Acad Sci U S A. 2007 Jul 17;104(29):12099-104. [PubMed]
  6. Serada S, Fujimoto M, Takahashi T, He P, Hayashi A, Tanaka T, Hagihara K, Yamadori T, Mochizuki M, Norioka N, Norioka S, Kawase I, Naka T.
    Proteomic analysis of autoantigens associated with systemic lupus erythematosus.
    Proteomics-clinical applications. Proteomics Clin Appl. 2007 Feb;1(2):185-91. [PubMed]

2006年

  1. Hirano T, Higa S, Arimitsu J, Naka T, Ogata A, Shima Y, Fujimoto M, Yamadori T, Ohkawara T, Kuwabara Y, Kawai M, Matsuda H, Yoshikawa M, Maezaki N, Tanaka T, Kawase I, Tanaka T.
    Luteolin, a flavonoid, inhibits AP-1 activation by basophils.
    Biochem Biophys Res Commun. 2006 Feb 3;340(1):1-7. [PubMed]
  2. Ouyang X, Fujimoto M, Nakagawa R, Serada S, Tanaka T, Nomura S, Kawase I, Kishimoto T, Naka T.
    SOCS-2 interferes with myotube formation and potentiates osteoblast differentiation through upregulation of JunB in C2C12 cells.
    J Cell Physiol. 2006 May;207(2):428-36. [PubMed]
  3. Arimitsu J, Hirano T, Higa S, Kawai M, Naka T, Ogata A, Shima Y, Fujimoto M, Yamadori T, Hagiwara K, Ohgawara T, Kuwabara Y, Kawase I, Tanaka T.
    IL-18 gene polymorphisms affect IL-18 production capability by monocytes.
    Biochem Biophys Res Commun. 2006 Apr 21;342(4):1413-6. [PubMed]
  4. Hirano T, Arimitsu J, Higa S, Naka T, Ogata A, Shima Y, Fujimoto M, Yamadori T, Ohkawara T, Kuwabara Y, Kawai M, Kawase I, Tanaka T.
    Luteolin, a flavonoid, inhibits CD40 ligand expression by activated human basophils.
    Int Arch Allergy Immunol. 2006;140(2):150-6. Epub 2006 Apr 4. [PubMed]
  5. Abe T, Nomura S, Nakagawa R, Fujimoto M, Kawase I, Naka T.
    Osteoblast differentiation is impaired in SOCS-1-deficient mice.
    J Bone Miner Metab. 2006;24(4):283-90. [PubMed]
  6. Ogata Y, Osaki T, Naka T, Iwahori K, Furukawa M, Nagatomo I, Kijima T, Kumagai T, Yoshida M, Tachibana I, Kawase I.
    Overexpression of PIAS3 suppresses cell growth and restores the drug sensitivity of human lung cancer cells in association with PI3-K/Akt inactivation.
    Neoplasia. 2006 Oct;8(10):817-25. [PubMed]

2005年

  1. Imanaka K, Tamura S, Fukui K, Ito N, Kiso S, Imai Y, Naka T, Kishimoto T, Kawata S, Shinomura Y; Kansai Viral Hepatitis Research Group.
    Enhanced expression of suppressor of cytokine signalling-1 in the liver of chronic hepatitis C: possible involvement in resistance to interferon therapy.
    J Viral Hepat. 2005 Mar;12(2):130-8. [PubMed]
  2. Seki E, Tsutsui H, Iimuro Y, Naka T, Son G, Akira S, Kishimoto T, Nakanishi K, Fujimoto J.
    Contribution of Toll-like receptor/myeloid differentiation factor 88 signaling to murine liver regeneration.
    Hepatology. 2005 Mar;41(3):443-50. [PubMed]
  3. Inaba M, Saito H, Fujimoto M, Sumitani S, Ohkawara T, Tanaka T, Kouhara H, Kasayama S, Kawase I, Kishimoto T, Naka T.
    Suppressor of cytokine signaling 1 suppresses muscle differentiation through modulation of IGF-I receptor signal transduction.
    Biochem Biophys Res Commun. 2005 Mar 25;328(4):953-61. [PubMed]
  4. Kimura A, Naka T, Muta T, Takeuchi O, Akira S, Kawase I, Kishimoto T.
    Suppressor of cytokine signaling-1 selectively inhibits LPS-induced IL-6 production by regulating JAK-STAT.
    Proc Natl Acad Sci U S A. 2005 Nov 22;102(47):17089-94. Epub 2005 Nov 15. [PubMed]

2004年

  1. Fujimoto M, Tsutsui H, Xinshou O, Tokumoto M, Watanabe D, Shima Y, Yoshimoto T, Hirakata H, Kawase I, Nakanishi K, Kishimoto T, Naka T.
    Inadequate induction of suppressor of cytokine signaling-1 causes systemic autoimmune diseases.
    Int Immunol. 2004 Feb;16(2):303-14. [PubMed]
  2. Komazaki T, Nagai H, Emi M, Terada Y, Yabe A, Jin E, Kawanami O, Konishi N, Moriyama Y, Naka T, Kishimoto T.
    Hypermethylation-associated inactivation of the SOCS-1 gene, a JAK/STAT inhibitor, in human pancreatic cancers.
    Jpn J Clin Oncol. 2004 Apr;34(4):191-4. [PubMed]
  3. Hirano T, Higa S, Arimitsu J, Naka T, Shima Y, Ohshima S, Fujimoto M, Yamadori T, Kawase I, Tanaka T.
    Flavonoids such as luteolin, fisetin and apigenin are inhibitors of interleukin-4 and interleukin-13 production by activated human basophils.
    Int Arch Allergy Immunol. 2004 Jun;134(2):135-40. [PubMed]
  4. Kimura A, Naka T, Kawase I, and Kishimoto T.
    SOCS-1 suppresses TNF-α-induced apoptosis through the regulation of Jak activation.
    Int Immunol. 2004; 16: 991-999. [PubMed]
  5. Watanabe D, Ezoe S, Fujimoto M, Kimura A, Saito Y, Nagai H, Tachibana I, Matsumura I, Tanaka T, Kanegane H, Miyawaki T, Emi M, Kanakura Y, Kawase I, Naka T, Kishimoto T.
    Suppressor of cytokine signalling-1 gene silencing in acute myeloid leukaemia and human haematopoietic cell lines.
    Br J Haematol. 2004 Sep;126(5):726-35. [PubMed]

2003年

  1. Nagai H, Naka T, Terada Y, Komazaki T, Yabe A, Jin E, Kawanami O, Kishimoto T, Konishi N, Nakamura M, Kobayashi Y, Emi M.
    Hypermethylation assiciated with inactivation of the SOCS-1 gene, a JAK/STAT inhibitor, in human hepatoblastomas.
    J Hum Genet. 2003;48(2):65-9. [PubMed]
  2. Ohnishi H, Yokoyama A, Yasuhara Y, Watanabe A, Naka T, Hamada H, Abe M, Nishimura K, Higaki J, Ikezoe J, Kohno N.
    Circulating KL-6 levels in patients with drug induced pneumonitis.
    Thorax. 2003 Oct;58(10):872-5. [PubMed]

2002年

  1. Sakuda S, Tamura S, Yamada A, Miyagawa Ji, Yamamoto K, Kiso S, Ito N, Imanaka K, Wada A, Naka T, Kishimoto T, Kawata S, Matsuzawa Y.
    Activation of signal transducer and activator transcription 3 and expression of suppressor of cytokine signal 1 during liver regeneration in rats.
    J Hepatol. 2002 Mar;36(3):378-84. [PubMed]
  2. Fujiwara H, Morita A, Kobayashi H, Hamano K, Fujiwara Y, Hirai K, Yano M, Naka T, Saeki Y.
    Infiltrating eosinophils and eotaxin: their association with idiopathic eosinophilic esophagitis.
    Ann Allergy Asthma Immunol. 2002 Oct;89(4):429-32. [PubMed]
  3. Fujimoto M, Tsutsui H, Yumikura-Futatsugi S, Ueda H, Xingshou O, Abe T, Kawase I, Nakanishi K, Kishimoto T, Naka T.
    A regulatory role for suppressor of cytokine signaling-1 in T(h) polarization in vivo.
    Int Immunol. 2002 Nov;14(11):1343-50. [PubMed]
  4. Seki Y, Hayashi K, Matsumoto A, Seki N, Tsukada J, Ransom J, Naka T, Kishimoto T, Yoshimura A, Kubo M.
    Expression of the suppressor of cytokine signaling-5 (SOCS5) negatively regulates IL-4-dependent STAT6 activation and Th2 differentiation.
    Proc. Natl. Acad. Sci. USA. 2002 Oct 1;99(20):13003-8. [PubMed]
  5. Nakagawa R, Naka T, Tsutsui H, Fujimoto M, Kimura A, Abe T, Seki E, Sato S, Takeuchi O, Takeda K, Akira S, Yamanishi K, Kawase I, Nakanishi K, Kishimoto T.
    SOCS-1 participates in negative regulation of LPS responses.
    Immunity. 2002 Nov;17(5):677-87. [PubMed]

2001年

  1. Kawazoe Y, Naka T, Fujimoto M, Kohzaki H, Morita Y, Narazaki M, Okumura K, Saitoh H, Nakagawa R, Uchiyama Y, Akira S, Kishimoto T.
    Signal transducer and activator of transcription (STAT)-induced STAT inhibitor 1 (SSI-1)/suppressor of cytokine signaling 1 (SOCS1) inhibits insulin signal transduction pathway through modulating insulin receptor substrate 1 (IRS-1) phosphorylation.
    J Exp Med. 2001 Jan 15;193(2):263-9. [PubMed]
  2. Naka T, Tsutsui H, Fujimoto M, Kawazoe Y, Kohzaki H, Morita Y, Nakagawa R, Narazaki M, Adachi K, Yoshimoto T, Nakanishi K, Kishimoto T.
    SOCS-1/SSI-1-deficient NKT cells participate in severe hepatitis through dysregulated cross-talk inhibition of IFN-γ and IL-4 signaling in vivo.
    Immunnity. 2001; 14: 535-545. [PubMed]

2000年以前

  1. Morita Y, Naka T, Kawazoe Y, Fujimoto M, Narazaki M, Nakagawa R, Fukuyama H, Nagata S, Kishimoto T.
    Signals transducers and activators of transcription (STAT)-induced STAT inhibitor-1 (SSI-1)/suppressor of cytokine signaling-1 (SOCS-1) suppresses tumor necrosis factor alpha-induced cell death in fibroblasts.
    Proc. Natl. Acad. Sci. USA. 2000 May 9;97(10):5405-10. [PubMed]
  2. Saito H, Morita Y, Fujimoto M, Narazaki M, Naka T, Kishimoto T.
    IFN regulatory factor-1-mediated transcriptional activation of mouse STAT-induced STAT inhibitor-1 gene promoter by IFN-gamma.
    J Immunol. 2000 Jun 1;164(11):5833-43. [PubMed]
  3. Fujimoto M, Naka T, Nakagawa R, Kawazoe Y, Morita Y, Tateishi A, Okumura K, Narazaki M, Kishimoto T.
    Defective thymocyte development and perturbed homeostasis of T cells in STAT-induced STAT inhibitor-1/suppressors of cytokine signaling-1 transgenic mice.
    J Immunol. 2000 Aug 15;165(4):1799-806. [PubMed]
  4. Naka T, Matsumoto T, Narazaki M, Fujimoto M, Morita Y, Ohsawa Y, Saito H, Nagasawa T, Uchiyama Y, Kishimoto T.
    Accelerated apoptosis of lymphocytes by augmented induction of Bax in SSI-1 (STAT-induced STAT inhibitor-1) deficient mice.
    Proc Natl Acad Sci USA. 1998 Dec 22;95(26):15577-82. [PubMed]
  5. Narazaki M, Fujimoto M, Matsumoto T, Morita Y, Saito H, Kajita T, Yoshizaki K, Naka T, Kishimoto T.
    Three distinct domains of SSI-1/SOCS-1/JAB protein are required for its suppression of interleukin 6 signaling.
    Proc. Natl. Acad. Sci. USA. 1998 Oct 27;95(22):13130-4. [PubMed]
  6. Minamoto S, Ikegame K, Ueno K, Narazaki M, Naka T, Yamamoto H, Matsumoto T, Saito H, Hosoe S, Kishimoto T.
    Cloning and functional analysis of new members of STAT induced STAT inhibitor (SSI) family: SSI-2 and SSI-3.
    Biochem Biophys Res Commun. 1997 Aug 8;237(1):79-83. [PubMed]
  7. Naka T, Narasaki M, Hirata M, Matsumoto T, Minamoto S, Aono A, Nishimoto N, Kajita T, Taga T, Yoshizaki K, Akira S, Kishimoto T.
    Structure and function of a new STAT-induced STAT inhibitor.
    Nature. 1997 Jun 26;387(6636):924-9. [PubMed]
  8. Ochi H, Tanaka T, Katada Y, Naka T, Aitani M, Hashimoto S, Maeda K, Toyoshima K, Igarashi T, Suemura M, Kishimoto T.
    Peripheral blood T lymphocytes and basophils, freshly isolated from house-dust-mite-sensitive patients, produce interleukin-4 in response to allergen-specific stimulation.
    Int Arch Allergy Immunol. 1996 Nov;111(3):253-61. [PubMed]
  9. Ochi H, Tanaka T, Katada Y, Naka T, Aitani M, Hashimoto S, Maeda K, Toyoshima K, Igarashi T, Suemura M.
    Functional disturbance of naive T lymphocytes in very high IgE producers: depletion of Interleukin-4-induced Interleukin-4-producing cells.
    Int Art Allergy Immunol. 1996 Mar;109(3):236-42. [PubMed]
  10. Fujiwara M, Kikutani H, Suematu S, Naka T, Yoshida K, Yoshida N, Tanaka T, Suemura M, Matsumoto N, Kojima S, Kishimoto T, Yoshida N.
    The absence of IgE antibody-mediated augmentation of immune responses in CD23-deficient mice.
    Proc. Natl. Acad. Sci. USA. 1994 Jul 19;91(15):6835-9. [PubMed]
  11. Kawabe T, Naka T, Yoshida K, Tanaka T, Fujiwara H, Suematsu S, Yoshida N, Kishimoto T, Kikutani H.
    The immune responses in CD40-deficient mice: impaired immunoglobulin class switching and germinal center formation.
    Immunity. 1994 Jun;1(3):167-78. [PubMed]

欧文総説

  1. Naka T, Fujimoto M, Kishimoto T.
    SSI-1 (STAT-Induced STAT I nhibitor-1); Negative regulation of cytokine signaling.
    Trends Biochem Sci. 1999; 24: 394-398. [PubMed]
  2. Naka T, Fujimoto M., Morita Y., Kishimoto T.
    Int. Cytokine Soc. Newsletter. 2000; 8: 1-10.
  3. Naka T, Kishimoto T.
    Joint disease caused by defective gp130-mediated STAT signaling.
    Arthritis Research 2002; 4: 154-156. [PubMed]
  4. Naka T, Nishimoto N, Kishimoto T.
    The paradigm of IL-6: from basic science to medicine.
    Arthriris Research 2002; 4: 233-242. [PubMed]
  5. Fujimoto M, Naka T.
    Regulation of cytokine signals by SOCS family molecules.
    Trend in Immunology. 2003;24: 659-666.
  6. Watanabe D, Naka T, Kishimoto T.
    Implication of SOCS-1 gene methylation in acute myeloid leukaemia.
    Br J Haematol. 2004 Dec;127(5):608-9. [PubMed]
  7. Naka T, Fujimoto M, Tsutsui H, Yoshimura A.
    Negative regulation of cytokine and TLR signaling by SOCS and others.
    Advanced Immunology. 2005; 87: 61-121. [PubMed]
  8. Yoshimura A, Naka T, Kubo M.
    SOCS proteins, cytokine signaling and immune regulation.
    Nature Review Immunology 2007; 7: 454-465. [PubMed]
  9. Kim A, Serada S, Enomoto T, Naka T.
    Targeting Annexin A4 to counteract chemoresistance in clear cell carcinoma of the ovary.
    Expert Opinion On Therapeutic Targets 2010; 14: 963-71. [PubMed]
  10. Fujimoto M, Naka T.
    SOCS1, a negative regulator of cytokine signals and TLR responses, in human liver diseases.
    Gastroenterology Research and Practice. Online journal 2010; Article ID 470468, 7 pages. (http://www.hindawi.com/journals/grp/2010/470468.html) [PubMed]
  11. Kim A, Ueda Y, Naka T, Enomoto T.
    Therapeutic strategies in epithelial ovarian cancer.
    J Exp & Clin Can Res 2012, 31:14. [PubMed]
  12. Matsuzaki S, Serada S, Morimoto A, Ueda Y, Yoshino K, Kimura T, Naka T.
    Annexin A4 is a promising therapeutic target for the treatment of platinum-resistant cancers.
    Expert Opin Ther Targets. 2014;18(4):403-14. [PubMed]
  13. Serada S, Naka T.
    Screening for Novel Serum Biomarker for Monitoring Disease Activity in Rheumatoid Arthritis Using iTRAQ Technology-Based Quantitative Proteomic Approach.
    Methods Mol Biol. 2014;1142:99-110. [PubMed]
ページの先頭へ